Pomalidomide (Imnovid®)

Assessment Status Assessment Process Complete
Drug Pomalidomide
Brand Imnovid®)
Indication In combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Assessment Process
Rapid review commissioned 20/09/2013
Rapid review completed 02/10/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 20/03/2014
NCPE assessment completed 10/03/2015
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations December 2015.